J Med Internet Res. 2014 Apr 7;16(4):e101. doi: 10.2196/jmir.2496.

Collaborative biomedicine in the age of big data: the case of cancer.

Shaikh AR1, Butte AJ, Schully SD, Dalton WS, Khoury MJ, Hesse BW.

Author information

• 1PricewaterhouseCoopers LLP, McLean, VA, United States. shaikh@us.pwc.com.

Abstract

Biomedicine is undergoing a revolution driven by high throughput and connective computing that is transforming medical research and practice. Using oncology as an example, the speed and capacity of genomic sequencing technologies is advancing the utility of individual genetic profiles for anticipating risk and targeting therapeutics. The goal is to enable an era of "P4" medicine that will become increasingly more predictive, personalized, preemptive, and participative over time. This vision hinges on leveraging potentially innovative and disruptive technologies in medicine to accelerate discovery and to reorient clinical practice for patient-centered care. Based on a panel discussion at the Medicine 2.0 conference in Boston with representatives from the National Cancer Institute, Moffitt Cancer Center, and Stanford University School of Medicine, this paper explores how emerging sociotechnical frameworks, informatics platforms, and health-related policy can be used to encourage data liquidity and innovation. This builds on the Institute of Medicine's vision for a "rapid learning health care system" to enable an open source, population-based approach to cancer prevention and control.